INSIGHTS ON DRUG DEVELOPMENT

• Why Biopharma Breakthroughs Aren't Moving The Market

  Biopharma is innovating fast but falling short commercially. Reveal key ecosystem gaps and five strategic actions to help strengthen resilience, accelerate performance, and futureproof organizations.

• AustinPx Site Tour

  Take a virtual tour of AustinPx to explore advanced facilities, including KinetiSol™ technology, and discover how we enable scalable, sustainable performance.

• API In Capsule Vs. The Lost Art Of Formulation Development

  API-in-capsule offers a fast path for early clinical data, but it can't eliminate the need for full formulation development. Weighing the potential for higher total development time and cost is critical.

• Building A Human-Centric Future For Biologics Development

  Biologics are advancing rapidly, but complexity challenges traditional models. Gain insight into how human-relevant approaches like NAMs and microphysiological systems are gaining traction.

• From Model To Molecule: Combining AI And Experimental Strategies To Transform Drug Development

  3/8/2026

  See how integrating AI-driven predictive modeling with well-designed experimental validation can help overcome development challenges, improve decision-making, and support accurate evaluation of API solid-state properties.

• Ask Us Anything: Miles Blackburn On Advances In Flow And Radical Chemistry

  7/23/2026

  Miles Blackburn, Associate Director of Chemistry at Snapdragon Chemistry, on why the biggest payoff of flow and radical chemistry is speed — processes that scale fast enough to get intermediates and APIs delivered on a clinical timeline.

• Take The Wheel And Drive Your Oligo Synthesis Where You Want

  2/9/2026

  Explore the evolving oligo therapeutic landscape while identifying common challenges of bringing production in‑house and the key factors that shape long‑term success for smoother scale‑up.

• Modifying The Micro-Environment To Improve Dissolution Rate

  6/11/2025

  Discover how modifying the micro-environment with targeted excipients can significantly enhance the dissolution rate of poorly soluble drugs using conventional manufacturing methods.

• Integrating Phase-Appropriate Quality Standards

  12/9/2024

  Incorporating phase-specific quality standards ensures GMP compliance. Collaborating with an experienced CDMO addresses late-stage quality needs and efficiently manages development timelines.